What is Leerink Partners's price target for SWAV?

Leerink Partners's latest stated price target for Shockwave Medical Inc. (SWAV) is $190, from its action on Feb 18, 2022.

What is Leerink Partners's rating on SWAV?

Leerink Partners rates SWAV Outperform, a bullish rating, as of Feb 18, 2022.

When did Leerink Partners last change its view on SWAV?

On Feb 18, 2022, Leerink Partners raises its price target to $190 from $160, keeps Outperform.

Analyst firms · Leerink Partners · SWAV

Leerink Partners SWAV price target and rating history

Shockwave Medical Inc. (SWAV) · Health Care

Leerink Partners rates Shockwave Medical Inc. (SWAV) Outperform with a $190 price target, as of its latest action on Feb 18, 2022. It has published 4 rating actions on SWAV since July 2021, including 0 upgrades and 0 downgrades.

Current rating: Outperform
Price target: $190
Median target, all firms: Too few
Actions on SWAV: 4

Leerink Partners price target on SWAV

Leerink Partners price target on SWAV, each point a stated target, July 2021 to February 2022.

Every Leerink Partners rating on SWAV

Feb 18, 2022
ReiterateLeerink Partners raises its price target to $190 from $160, keeps Outperform
Nov 9, 2021
ReiterateLeerink Partners raises its price target to $265 from $250, keeps Outperform
Aug 10, 2021
ReiterateLeerink Partners raises its price target to $220 from $208, keeps Outperform
Jul 15, 2021
InitiateLeerink Partners starts coverage at Outperform, price target $208

Questions about Leerink Partners and SWAV

What is Leerink Partners's price target for SWAV?: Leerink Partners's latest stated price target for Shockwave Medical Inc. (SWAV) is $190, from its action on Feb 18, 2022.
What is Leerink Partners's rating on SWAV?: Leerink Partners rates SWAV Outperform, a bullish rating, as of Feb 18, 2022.
When did Leerink Partners last change its view on SWAV?: On Feb 18, 2022, Leerink Partners raises its price target to $190 from $160, keeps Outperform.

More SWAV rating histories

All Leerink Partners ratings SWAV news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.